CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs

CMS selected 15 high-cost Medicare drugs (including, for the first time, Part B-payable drugs) for the third cycle of the Medicare Drug Price Negotiation Program and designated one previously negotiated drug (Tradjenta) for renegotiation; negotiations will occur in 2026 with any agreed prices effective January 1, 2028. The selected medicines were used by about 1.8 million Medicare beneficiaries and accounted for roughly $27 billion in Part B and D spending (~6% of combined spending); CMS noted prior-cycle negotiated prices would have reduced 2024 net covered drug costs by an estimated $8.5 billion (about 36%). The program increases regulatory downside risk to revenue streams for manufacturers of listed drugs and warrants focused exposure review for affected pharma names ahead of 2026 negotiations.

Analysis

Market structure: Medicare’s selection targets high-revenue branded drugs (15 drugs = ~$27bn, ~6% of Part B/D spend). Direct losers are manufacturers with concentrated Medicare exposure (examples: PFE, LLY, ABBV, GILD, NVS, BMY, TAK) as negotiated prices could compress unit revenues by a similar order to cycle 2 (~30–40% net reduction seen as a reference). Winners are payers/MA plans and taxpayers; PBMs/insurers (UNH, CVS, CI) can see margin relief on pharmacy spend but may face shrinking rebate pools.

Risk assessment: Tail risks include policy broadening (program expansion to >30 drugs) or international price-linking that cuts ex‑US pricing — a >20% revenue shock for specific names is plausible in a downside scenario. Timing: immediate market moves likely muted; key binary dates are Feb 28, 2026 (participation opt-in) and calendar 2026 negotiations with prices effective 1/1/2028; expect guidance cuts and volatility across 2026–2028. Hidden dependency: commercial pricing and rebate architectures may reprice, propagating impact beyond Medicare and accelerating biosimilar uptake.

Trade implications: Favor underweight/high-conviction shorts in single-name exposure to listed drugs and long selective payers/generics. Use Jan 2028-dated option structures to align with effective date (buy protective puts or put spreads on high-exposure pharma; buy call spreads on UNH/CVS to capture margin tailwind). Phasing: scale 25–50% now, add or trim after Feb 28, 2026 participation announcements.

Contrarian angles: Consensus assumes permanent 30–40% realized cuts; that may be overstated because companies can (a) refuse participation, (b) shift sales mixes/commercial priceings, or (c) offset with non‑Medicare growth. Historical parallel: prior cycles produced headline savings but limited long-term market-cap destruction for diversified pharma. If a broad sell-off >8–12% in large-cap pharma occurs, tactical dip-buy of diversified names (PFE, NVS) merits consideration.

Key Decisions for Investors

• Establish a 2–3% portfolio short via Jan‑2028 bear put spreads on Pfizer (PFE) and AbbVie (ABBV) targeting strikes 10–15% below current price to hedge revenue downside tied to Xeljanz/Botox; size to limit max loss to ~2% each.
• Add a 2–4% tactical long in payer exposure: buy UNH and CVS call spreads (expiry Jan‑2028) to capture expected Medicare Advantage margin tailwind; allocate equally and cap downside by spreads.
• Initiate a 1–2% long position in generics/biosimilar manufacturers (e.g., TEVA or SBLK exposure via ETF XBI/IBB tilt) to benefit from accelerated switch to lower-cost alternatives; increase to 3–4% if participation opt‑ins exceed 10 of selected firms on Feb 28, 2026.
• Reduce outright long exposure to sector ETF XLV by 3–5% and redeploy proceeds into quality defensive sectors (Staples, Utilities) if any single-name pharma falls >8% intra‑day on news; re-evaluate after participation decisions in Feb 2026.
• Monitor three hard triggers and act: (A) Feb 28, 2026 – if >50% of manufacturers opt in, increase short exposure by 50%; (B) mid‑2026 final offers – close >50% of option time decay; (C) 1/1/2028 – unwind hedges gradually as realized price impacts become visible in 2028 guidance.